GSK's anti-BCMA drug hits goal in pivotal multiple myeloma test

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Aug 23, 2019 at 10:32 AM.

  1. #1 cafead, Aug 23, 2019 at 10:32 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,046
    Likes Received:
    3
    via A phase 2 trial of GlaxoSmithKline’s BCMA drug has hit its primary endpoint, keeping Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year.

    article source
     
    Quote

Reply to Thread